Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Investor Presentation for Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st Decmeber 2023. Piramal Pharma Ltd - 543635 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December, 2023
Unaudited Financial results (standalone & consolidated) for the quarter and nine months ended 31st December 2023 Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Piramal Pharma Limited (The 'Company') Held On 30Th January, 2024
Outcome of Board Meeting dated 30th January 2024 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations') Piramal Pharma Ltd - 543635 - Board Meeting Intimation for Quarter Ended 31St December, 2023.
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 31st December, 2023. Piramal Critical Care expands generic injectables portfolio
Piramal Pharma stock edges up on NSE Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation of Press Release regarding launch of new 10mg/10ml (1mg/ml) concentration of Zinc Sulfate for Injection USP in the United States of America. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation of Press Release regarding opening of Antibody-Drug Conjugate ("ADC") manufacturing expansion in Grangemouth, Scotland.
Piramal Pharma allocates Rs 330 crore towards capex H2FY24
Firm targets Rs 1,000 crore growth in consumer health business